Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 6864135, 8 pages
http://dx.doi.org/10.1155/2016/6864135
Research Article

Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells

Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China

Received 19 January 2016; Revised 13 March 2016; Accepted 20 March 2016

Academic Editor: Stefan Knapp

Copyright © 2016 Xi Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Raab, K. Podar, I. Breitkreutz, P. G. Richardson, and K. C. Anderson, “Multiple myeloma,” The Lancet, vol. 374, no. 9686, pp. 324–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. D. Collins, “Problems monitoring response in multiple myeloma,” Cancer Imaging, vol. 5, pp. S119–S126, 2005. View at Google Scholar · View at Scopus
  3. J.-H. Hsu, Y. Shi, S. Krajewski et al., “The AKT kinase is activated in multiple myeloma tumor cells,” Blood, vol. 98, no. 9, pp. 2853–2855, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Andrabi, O. V. Gjoerup, J. A. Kean, T. M. Roberts, and B. Schaffhausen, “Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 48, pp. 19011–19016, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Côme, A. Laine, M. Chanrion et al., “CIP2A is associated with human breast cancer aggressivity,” Clinical Cancer Research, vol. 15, no. 16, pp. 5092–5100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Ersahin, N. Tuncbag, and R. Cetin-Atalay, “The PI3K/AKT/mTOR interactive pathway,” Molecular Biosystems, vol. 11, no. 7, pp. 1946–1954, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. Q. Zhang and F. X. Claret, “Phosphatases: the new brakes for cancer development?” Enzyme Research, vol. 2012, Article ID 659649, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Sablina, M. Hector, N. Colpaert, and W. C. Hahn, “Identification of PP2A complexes and pathways involved in cell transformation,” Cancer Research, vol. 70, no. 24, pp. 10474–10484, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. Junttila, P. Puustinen, M. Niemelä et al., “CIP2A inhibits PP2A in human malignancies,” Cell, vol. 130, no. 1, pp. 51–62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Khanna, C. Böckelman, A. Hemmes et al., “MYC-dependent regulation and prognostic role of CIP2A in gastric cancer,” Journal of the National Cancer Institute, vol. 101, no. 11, pp. 793–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Li, Z. Ge, C. Liu et al., “CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells,” Clinical Cancer Research, vol. 14, no. 12, pp. 3722–3728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. L. S. Hoo, J. Y. Zhang, and E. K. L. Chan, “Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer,” Oncogene, vol. 21, no. 32, pp. 5006–5015, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Khanna and J. E. Pimanda, “Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers,” International Journal of Cancer, vol. 138, no. 3, pp. 525–532, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Shen, R. Wu, B. Liu et al., “Upstream and downstream mechanisms for the promoting effects of IGF-1 on differentiation of spermatogonia to primary spermatocytes,” Life Sciences, vol. 101, no. 1-2, pp. 49–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Böckelman, H. Lassus, A. Hemmes et al., “Prognostic role of CIP2A expression in serous ovarian cancer,” British Journal of Cancer, vol. 105, no. 7, pp. 989–995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. Q.-Z. Dong, Y. Wang, X.-J. Dong et al., “CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis,” Annals of Surgical Oncology, vol. 18, no. 3, pp. 857–865, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Xue, G. Wu, X. Wang et al., “CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma,” Medical Oncology, vol. 30, no. 1, article 406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. H. He, G. Wu, W. Li, Y. Cao, and Y. Liu, “CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis,” Diagnostic Molecular Pathology, vol. 21, no. 3, pp. 143–149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Qu, W. Li, L. Wei, L. Xing, X. Wang, and J. Yu, “CIP2A is overexpressed in esophageal squamous cell carcinoma,” Medical Oncology, vol. 29, no. 1, pp. 113–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. C. M. Lucas, R. J. Harris, A. Giannoudis, M. Copland, J. R. Slupsky, and R. E. Clark, “Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression,” Blood, vol. 117, no. 24, pp. 6660–6668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Wiegering, C. Pfann, F. W. Uthe et al., “CIP2A influences survival in colon cancer and is critical for maintaining Myc expression,” PLoS ONE, vol. 8, no. 10, Article ID e75292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Y.-C. Lin, K.-C. Chen, C.-C. Chen, A.-L. Cheng, and K.-F. Chen, “CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells,” Oral Oncology, vol. 48, no. 7, pp. 585–593, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L.-M. Tseng, C.-Y. Liu, K.-C. Chang, P.-Y. Chu, C.-W. Shiau, and K.-F. Chen, “CIP2A is a target of bortezomib in human triple negative breast cancer cells,” Breast Cancer Research, vol. 14, no. 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. P. De, J. Carlson, B. Leyland-Jones, and N. Dey, “Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands,” Oncotarget, vol. 5, no. 13, pp. 4581–4602, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. H.-C. Yu, H.-J. Chen, Y.-L. Chang et al., “Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma,” Biochemical Pharmacology, vol. 85, no. 3, pp. 356–366, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Cantini, C. C. Attaway, B. Butler, L. M. Andino, M. L. Sokolosky, and A. Jakymiw, “Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells,” PLoS ONE, vol. 8, no. 9, Article ID e73348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-Y. Liu, C.-W. Shiau, H.-Y. Kuo et al., “Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells,” Haematologica, vol. 98, no. 5, pp. 729–738, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. T.-T. Chao, C.-Y. Wang, Y.-L. Chen et al., “Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A,” Oncotarget, vol. 6, no. 4, pp. 2164–2179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. H.-C. Yu, M.-H. Hung, Y.-L. Chen et al., “Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A,” Cell Death and Disease, vol. 5, no. 7, Article ID e1359, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Mabuchi, H. Kuroda, R. Takahashi, and T. Sasano, “The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer,” Gynecologic Oncology, vol. 137, no. 1, pp. 173–179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. K.-F. Chen, C.-Y. Liu, Y.-C. Lin et al., “CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells,” Oncogene, vol. 29, no. 47, pp. 6257–6266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Lei, B. Peng, and J.-Y. Zhang, “CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer,” Oncology Reports, vol. 32, no. 4, pp. 1689–1694, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Kumar and K. Tikoo, “Independent role of PP2A and mTORc1 in palmitate induced podocyte death,” Biochimie, vol. 112, pp. 73–84, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Hartley and G. M. Cooper, “Role of mTOR in the degradation of IRS-1: regulation of PP2A activity,” Journal of Cellular Biochemistry, vol. 85, no. 2, pp. 304–314, 2002. View at Publisher · View at Google Scholar · View at Scopus